Clearside Biomedical

Clearside Biomedical Supply Chain

Delisted

Supply Chain of Clearside Biomedical (CLSD) as of Nov 20, 2026.

Supply Chain

-

Last updated:

Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.

Clearside Biomedical Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
4 companies
#NameTrend
1
Bausch Health
Supplier·Customer·CA
0.64
0.77
0.64
0.58
0.70
0.62
2
REGENXBIO
Supplier·Customer·Biotechnology·US
0.63
0.83
0.69
0.75
0.77
0.42
#NameTrend
1
Aura Biosciences
Supplier·Customer·Biotechnology·US
0.61
0.30
0.83
0.04
—
—
2
Gerresheimer
Supplier·Customer·Life Sciences Tools & Services·DE
-0.28
-0.51
0.11
0.57
0.76
0.08

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

All Key Metrics — Clearside Biomedical